New York Times reports on price cuts for HPV vaccine

Thanks to Pap tests, fatal cervical cancers are almost unknown today in rich countries. But the disease kills an estimated 275,000 women a year in poor countries where Pap tests are impractical and the vaccine is far too expensive for the average woman to afford, so the price cut could lead to a significant advance in women’s health.

Last week in separate deals with the GAVI Alliance, the drug companies Pfizer and GlaxoSmithKline (GSK) agreed to increase sales of cut-price pneumonia vaccines by 180 million doses, a 50% increase from previous commitments.

Subscribe to RSS - GlaxoSmithKline